Loading
institutionsInstitution
Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre
South London's cancer centre with King's College London, strong in breast and prostate cancer, radiotherapy and large screening trials such as NHS-Galleri.
Also called: Guy's Cancer CentreGSTTKing's College London Comprehensive Cancer Centre
Overview
Guy's Cancer Centre, opened in 2016, brings together cancer care for Guy's and St Thomas' and forms, with King's College London and King's College Hospital, the King's Health Partners Comprehensive Cancer Centre. King's School of Cancer and Pharmaceutical Sciences hosts the Breast Cancer Now Research Unit, where Andrew Tutt led clinical development of PARP inhibitors in BRCA-mutated breast cancer including the OlympiA trial, and the Cancer Prevention Trials Unit under Peter Sasieni, which runs the NHS-Galleri multi-cancer early detection trial with Cancer Research UK. The trust has one of the largest radiotherapy services in the UK, a leading robotic urology and prostate programme, and is part of the CRUK City of London Centre.
Location
London, GB
Type
hospital · King's College London
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#58 · 48 points (0 Newsweek + 0 NCI + 48 from 24 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Guy's and St Thomas' NHS Foundation Trust, including child institutions. 735 works · 7,432 citations · 75% open access · 13% clinical trials · 4% reviews.
Oncology works per year
1772022
1482023
1402024
1552025
1152026
Most works
- Mieke Van Hemelrijck39 works
- Rebecca Sophie Kristeleit31 works
- Debashis Sarker28 works
- John F. Maher26 works
- Sophia N. Karagiannis24 works
- Ajay Kumar Aggarwal23 works
- James F. Spicer20 works
- Richard Sullivan19 works
- Sophie Papa16 works
- Eleni M. Karapanagiotou16 works
Most cited
- Breast cancer and PARP inhibitors
- Cancer Prevention Trials Unit (NHS-Galleri)
- Prostate and urology
- Radiotherapy
- Haemato-oncology
Amanda Pritchard
Chief Executive of Guy's and St Thomas' NHS Foundation Trust
Health service leadershipNHS managementHospital operations
Former head of NHS England who returned to lead Guy's and St Thomas' NHS Foundation Trust as Chief Executive in September 2025.
Claire Harrison
Professor of Myeloproliferative Neoplasms and Clinical Director of Haematology, Guy's and St Thomas' NHS Foundation Trust
Myeloproliferative neoplasmsMyelofibrosisJAK inhibitors
Led COMFORT-II, which established ruxolitinib as the first drug for myelofibrosis, and most UK MPN trials since.
Andrew Tutt
Director, Breast Cancer Now Toby Robins Research Centre, ICR; Consultant Clinical Oncologist, Royal Marsden and Guy's
Triple-negative breast cancerBRCA and DNA repairPARP inhibitors
Led OlympiA, the trial that showed a year of olaparib after surgery improves survival in BRCA-mutated breast cancer.
Similar pages
- Key paperSustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial
Shares Andrew Tutt, OlympiA, PARP inhibitors, Olaparib.
- Key paperOverall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Shares Andrew Tutt, OlympiA, PARP inhibitors, Olaparib.
- PairingGermline BRCA test → adjuvant PARP inhibitor
Shares OlympiA, PARP inhibitors, Olaparib, Triple-negative breast cancer (TNBC).
- IdeaMulti-cancer blood test as the first step for patients with non-specific symptoms
Shares GRAIL, Galleri, Multi-cancer early detection (MCED).
- PersonPeter Sasieni
Shares Galleri, NHS-Galleri, Multi-cancer early detection (MCED), Cancer Research UK.
- PersonEric A. Klein
Shares Galleri, NHS-Galleri, Multi-cancer early detection (MCED), Prostate cancer.
- IdeaPre-agreed update rules so an MCED test is not obsolete when its trial reads out
Shares GRAIL, NHS-Galleri, Multi-cancer early detection (MCED).
- Key paperOlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer
Shares Andrew Tutt, OlympiA, PARP inhibitors, Olaparib.